Pharvaris N.V. Stock Price, News & Analysis

Pharvaris (PHVS) reported a strong financial position with cash and equivalents of €238.3 million as of March 31, 2021. The company is advancing its Phase 2 studies for PHVS416, an oral treatment for hereditary angioedema (HAE), with the RAPIDe-1 on-demand study underway and the HAE CHAPTER-1 prophylactic study set to initiate in 2021. The leadership team has expanded with the appointment of Wim Souverijns as chief community engagement & commercial officer and the nomination of Viviane Monges to the Board of Directors.

Pharvaris (Nasdaq: PHVS) has appointed Wim Souverijns, Ph.D., as Chief Community Engagement & Commercial Officer, effective July 1, 2021. With over 25 years of experience in pharmaceutical leadership, Souverijns will enhance Pharvaris' engagement with the HAE community and support the commercialization of PHVS416 and PHVS719. This strategic appointment aims to bolster the company's clinical development programs and market readiness for its oral bradykinin-B2-receptor antagonists. Pharvaris focuses on innovative treatments for hereditary angioedema (HAE).

Pharvaris (Nasdaq: PHVS) announced key updates regarding its clinical pipeline and financial standing as of December 31, 2020. The company is actively enrolling patients in the Phase 2 RAPIDe-1 clinical trial for PHVS416, an oral therapy for hereditary angioedema (HAE). Pharvaris has a robust cash position of €98.6 million following its IPO, enabling continued research and development efforts, including upcoming prophylactic studies of PHVS416 and PHVS719. Despite a net loss of €26.0 million for 2020, the company remains optimistic about advancing treatments for HAE.

Pharvaris (Nasdaq: PHVS) announced the FDA's acceptance of its Investigational New Drug (IND) application for PHVS416, an oral bradykinin-B2-receptor antagonist aimed at treating hereditary angioedema (HAE). This milestone paves the way for a prophylactic study, complementing the ongoing Phase 2 clinical trial for on-demand treatment. PHVS416 offers a softgel formulation of the previously studied PHA121, which has shown promising results in earlier trials. Pharvaris aims to provide effective oral alternatives for HAE patients.

Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on oral bradykinin-B2-receptor antagonists for hereditary angioedema (HAE), announced CEO Berndt Modig's participation in BioCapital Europe. The event will feature a panel presentation titled “Shaping the New Biotech Reality – Key Lessons from COVID” on March 10, 2021, at 18:30 CET. Additionally, a corporate presentation will occur on March 11, 2021, at 14:50 CET. Both presentations will be accessible for 30 days on the Pharvaris website.

Pharvaris (Nasdaq: PHVS) has initiated the RAPIDe-1 Phase 2 study, dosing the first patient for its oral bradykinin B2 receptor antagonist, PHVS416, targeting hereditary angioedema (HAE) treatment. The trial will evaluate the efficacy, safety, and pharmacokinetics of PHVS416 in 54 adult patients with HAE type 1 or 2 across North America and Europe. The results aim to provide rapid and convenient on-demand treatment for HAE attacks, offering an alternative to injectable therapies. Pharvaris' approach could significantly enhance patient care for this rare condition.

Pharvaris (Nasdaq: PHVS) announced the presentation of clinical data for PHA121 at the 2021 AAAAI Virtual Annual Meeting. This single-dose treatment showed effective bradykinin inhibition in healthy volunteers, supporting initiation of studies in hereditary angioedema (HAE) patients this year. Results indicated that PHA121 achieves therapeutic levels quickly, with significant pharmacodynamic effects compared to icatibant. Adverse events were reported in 25% of subjects, consistent with placebo, and were mild or moderate. The company aims to develop both on-demand and prophylactic treatments using PHA121.

Pharvaris N.V. (Nasdaq: PHVS) has successfully closed its initial public offering, issuing 9,511,075 ordinary shares at $20.00 each, generating approximately $190.2 million in gross proceeds. This includes the full exercise of the underwriters' option to purchase an additional 1,240,575 shares. The shares commenced trading on February 5, 2021. Pharvaris focuses on developing small molecule bradykinin-B2-receptor antagonists for hereditary angioedema (HAE) and other related conditions, exemplifying its commitment to innovative therapeutic solutions.

Pharvaris N.V., a clinical-stage biopharmaceutical company, announced the pricing of its upsized initial public offering of 8,270,500 ordinary shares at $20.00 per share, totaling gross proceeds of approximately $165.4 million. The offering includes a 30-day over-allotment option for an additional 1,240,575 shares. Shares will trade on the Nasdaq under the symbol PHVS starting February 5, 2021. The offering aims to advance Pharvaris's development of oral bradykinin-B2-receptor antagonists for hereditary angioedema and other conditions.